Enlivex Therapeutics Ltd.
14 Einstein Street
Nes Ziona
Israel 7403618
July 5, 2019
Via EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Attention: | Ada D. Sarmento |
| Re: | Enlivex Therapeutics Ltd. |
Registration Statement filed on Form F-3
Filed on June 28, 2019
File No. 333-232413
Dear Ms. Sarmento:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Enlivex Therapeutics Ltd. (the “Company”) hereby requests acceleration of the effective date of the above-referenced registration statement so that it will become effective at 5:00 p.m., Eastern Daylight Time, on Tuesday, July 9, 2019, or as soon as practicable thereafter.
Should you have any questions or comments regarding this matter, please contact the undersigned at +972.2.6708072 or the Company’s legal counsel, Robert L. Grossman, Esq. at (305) 579-0756 or Drew Altman, Esq. at (305) 579-0589, each of Greenberg Traurig, P.A.
The Company hereby authorizes Drew M. Altman of Greenberg Traurig, P.A. to orally modify or withdraw this request for acceleration.
| Sincerely, | ||
| Enlivex Therapeutics, Ltd. | ||
| By: | /s/ Shai Novik | |
| Name: | Shai Novik | |
| Title: | Executive Chairman | |
| cc: | Robert L. Grossman, Esq. |
Drew M. Altman, Esq.
Greenberg Traurig, P.A.
